HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GYKI 47261

structure in first source

Also Known As:

GYKI-47261

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        GYKI 47261: 1

Experts

1.	Bibbiani, F: 1 article (12/2005)
2.	Chase, T N: 1 article (12/2005)
3.	Collins, M A: 1 article (12/2005)
4.	Kielaite, A: 1 article (12/2005)
5.	Oh, J D: 1 article (12/2005)
6.	Smith, C: 1 article (12/2005)

Related Diseases

1.	Dyskinesias (Dyskinesia) 12/01/2005 - "The effects of GYKI-47261 and amantadine (or MK-801), alone and in combination, were compared for their ability to modify dyskinesias induced by levodopa. " 12/01/2005 - "In primates, the glutamate antagonists GYKI-47261 and amantadine, co-administered at low doses (failing to alter dyskinesia scores), reduced levodopa-induced dyskinesias by 51% (P < 0.05). "
2.	Parkinson Disease (Parkinson's Disease) 12/01/2005 - "To evaluate the contribution of both glutamate receptor types to the pathogenesis of motor response alterations associated with dopaminergic treatment, we studied the ability of the selective AMPA receptor antagonist GYKI-47261 and the selective NMDA receptor antagonists, MK-801 and amantadine, to mitigate these syndromes in rodent and primate models of Parkinson's disease. "

Related Drugs and Biologics

1.	Excitatory Amino Acid Antagonists
2.	AMPA Receptors (AMPA Receptor)
3.	Glutamate Receptors (Glutamate Receptor)
4.	Dizocilpine Maleate (Dizocilpine)
5.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
6.	Levodopa (L Dopa)
7.	Amantadine (Aman)